Evaluating the DRUP Trial: Insights into Off-Label Cancer Treatments

The DRUP trial, initiated in 2016, has provided off-label treatment opportunities for over 1,600 patients with advanced cancers lacking standard therapeutic options. Notably, 39.1% of these patients had rare cancers, which often have limited treatment avenues. The trial reported a clinical benefit rate of 34.9%, with 15.7% achieving an objective response and 7.0% classified as exceptional responders. These outcomes align with other precision oncology trials, such as NCI-MATCH and MyPathway, indicating a stable efficacy profile over the study's duration.

Nature

Despite the potential benefits, the DRUP trial highlighted significant challenges associated with off-label drug use. A considerable 28.4% of participants experienced grade 3 or higher treatment-related adverse events (TRAEs). The financial burden on healthcare systems is exacerbated by high drug prices and inconsistent reimbursement policies. These issues have prompted calls for stricter regulations governing off-label drug use, advocating for structured initiatives like DRUP to mitigate risks while providing controlled access to treatments.

Nature

The trial identified several exceptional responders across various molecular subgroups, demonstrating the promise of precision oncology. For instance, patients with BRAF p. V600E-mutated brain tumors showed significant benefits. The study emphasized the importance of selecting molecular targets with strong biological rationale and prior clinical evidence, as reflected in classification systems like the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Nature

Despite achieving predefined success criteria in 14 cohorts, only one progressed to a third-stage expansion. Factors hindering this advancement included the misalignment of success thresholds with current regulatory standards and the expiration of drug patents, which diminished pharmaceutical interest. The trial's design also faced challenges due to the rarity of certain indications and the uneven access to comprehensive molecular diagnostics, which likely resulted in missed eligible patients.

Nature

The findings from DRUP suggest that off-label precision medicines should be confined to structured, data-generating frameworks to ensure safety and efficacy. Enhanced collaboration across European countries, as seen in initiatives like PCM4EU and PRIME-ROSE, is crucial for accelerating enrollment and validating promising findings. As the field of oncology evolves, improved biological understanding and more effective therapies may enhance patient outcomes, but until then, careful biomarker selection and systematic outcome monitoring remain essential.

Nature

The DRUP trial's outcomes underscore the necessity of robust evidence and careful evaluation in off-label drug use. The study advocates for a structured approach to treatment, emphasizing that while off-label precision medicines can be effective, they should only be utilized within clinical trial settings that prioritize data collection and monitoring.

Nature

• “These positive signals underscore that effective off-label use is possible, but that it requires robust evidence, careful biomarker selection and prospective evaluation to ensure stepwise drug evaluation towards potential label expansion.” — DRUP Research Team

Nature

• “Rather, our experiences from 2016 to 2024 strongly argue for confining off-label use to structured, data-generating frameworks until new advancements prove otherwise to allow for a better informed and safer choice of treatment.” — DRUP Research Team

Nature

• “However, in the absence of a framework to systematically capture outcomes, this practice carries significant risks of toxicity, costs and inequitable access.” — DRUP Research Team

Nature